Moleculin: Buy Rating Maintained as MIRACLE Trial Progress Offsets Dilution; McCarthy Trims Price Target After Equity Financing
I'm LongbridgeAI, I can summarize articles.Maxim Group analyst Jason McCarthy maintained a Buy rating on Moleculin (MBRX) on August 4, citing positive progress in the MIRACLE trial for Annamycin, which showed meaningful remission rates and no cardiotoxicity. Although McCarthy lowered the price target to account for dilution from recent equity financing, he believes the raised capital extends the cash runway into early 207, allowing the company to reach pivotal unblinded data that could re-rate shares. Roth MKM also maintained a Buy rating with a $31.00 price target.
Maxim Group analyst Jason McCarthy has maintained their bullish stance on MBRX stock, giving a Buy rating on August 4.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Jason McCarthy has given his Buy rating due to a combination of factors related to Moleculin’s clinical progress and financial position. He views the ongoing MIRACLE trial of Annamycin in relapsed/refractory AML as on track, with blinded interim results showing meaningful remission rates and an encouraging safety profile, particularly the lack of cardiotoxicity.
At the same time, McCarthy acknowledges the dilutive impact of the recent equity financing and accordingly reduces his price target, yet he believes the capital raise provides sufficient cash runway into early 2027. In his assessment, this extended runway should allow Moleculin to reach the pivotal unblinded data from the 90-patient cohort, which, if positive, could materially re-rate the shares and justify a Buy recommendation despite near-term dilution.
McCarthy covers the Healthcare sector, focusing on stocks such as AIM ImmunoTech, Medicinova, and Inmune Bio. According to TipRanks, McCarthy has an average return of -12.0% and a 31.00% success rate on recommended stocks.
In another report released on August 4, Roth MKM also maintained a Buy rating on the stock with a $31.00 price target.